National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

pertuzumab
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:2C4 antibody
monoclonal antibody 2C4
rhuMAb-2C4
US brand name:Omnitarg
Abbreviation:MOAB 2C4



Previous:Periactin, perifosine, perillyl alcohol, Permitil, Persantine
Next:petrolatum-mineral oil-lanolin-ceresin ointment, PF-00299804, PGLA/PEG copolymer-based paclitaxel, PHA-739358, Phenergan

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov